Celcuity

Celcuity Financing Cash Flow

The Net Financing Cash Flow of Celcuity (CELC) as of Nov 11, 2026 is 360.55 M USD. In the previous year, Net Financing Cash Flow was 138.39 M USD — a change of 160.54% (higher).

Financing Cash Flow

360.55 MUSD

YoY

160.54%

Last updated:

Net Financing Cash Flow of Celcuity is 2025 360.55 M USD. Net Financing Cash Flow of Celcuity was 2024 138.39 M USD. It decreases by 160.54% higher compared to the previous year.

The Celcuity Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
236,697.00 USD
Jan 1, 2019
259,305.00 USD
Jan 1, 2020
137,969.00 USD
Jan 1, 2021
93.04 M USD
Jan 1, 2022
120.33 M USD
Jan 1, 2023
64.91 M USD
Jan 1, 2024
138.39 M USD
Jan 1, 2025
360.55 M USD
The Celcuity Financing Cash Flow history
YEARFinancing Cash FlowYoY
360.55 MUSD+160.54%
138.39 MUSD+113.19%
64.91 MUSD-46.05%
120.33 MUSD+29.32%
93.04 MUSD+67,336.75%
137,969.00USD-46.79%
259,305.00USD+9.55%
236,697.00USD-99.23%
30.71 MUSD+725.87%
3.72 MUSD-22.57%
4.80 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

Net Financing Cash Flow of Celcuity is 360.55 M USD in 2025.

Net Financing Cash Flow of Celcuity changed from 138.39 M USD to 360.55 M USD, representing a 160.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Celcuity since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Celcuity historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Celcuity

All Key Metrics — Celcuity